The sales of medicines for Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) in Canada are projected to decline gradually from $654.0 million in 2024 to $622.6 million in 2028. This indicates a noticeable deceleration with a compound annual growth rate (CAGR) decreasing over the forecast period. In 2023, the actual sales were higher than those forecasted for 2024, showcasing a downtrend that seems likely to continue.

Future trends to watch for:

Potential shifts in market dynamics could arise from the introduction of new therapies or generic medications.
Changes in healthcare policies or pricing regulations may further impact sales volumes and values.
Increasing awareness and early diagnosis might offset sales declines for certain segments.